semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Hypogonadotropic Hypogonadism Healthy Postmenopausal Women Agonadism A. Healthy Subjects All healthy subjects will meet the following normal puberty with respect to onset and pace no difficulty with blood draws no prescription medications for at least 2 months with the exception of asthma medication (albuterol only), hypercholesterolemia medication and psychiatric medication no illicit drug use or excessive alcohol consumption (>10 drinks/week) no history of a medication reaction requiring emergency medical care normal physical exam and laboratory studies within protocol reference ranges. Additional based on subject population: 1. Healthy Men between 21 and 40 years old normal erectile and ejaculatory function, no history of reproductive disorders testicular volume >15 ml. 2. Healthy women
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Breast Cancer A confirmed histological diagnosis of invasive breast carcinoma or DCIS 2. Age greater or equal to 50 years old 3. Life expectancy > 6 months 4. Treated by breast conserving surgery with axillary node dissection or sentinel lymph node biopsy 5. Pathologic tumor size less than or equal to 2 cm 6. Invasive ductal, mucinous, tubular or colloid histology 7. Estrogen receptor positive for invasive carcinoma. 8. Unifocal/unicentric disease 9. Negative surgical margins greater than or equal to 2 mm 10. Pathologic lymph node negative 11. No evidence of lymphovascular invasion 12. ECOG performance status of 0 or 1 (Appendix 1) 13. Informed consent signed  Known BRCA 1/2 Mutation; (BRCA 1 and 2 testing is not required) 2. Autoimmune disorder 3. Pregnancy 4. Breast implants 5. Psychiatric or addictive disorder that would preclude attending follow-up 6. Neoadjuvant chemotherapy (adjuvant chemotherapy is permitted) 7. Suspicious remaining microcalcification on post-surgery mammogram (unless biopsy proven benign) 8. Lobular features on histology (pure or mixed) or sarcoma histology 9. Node positive on axillary dissection or in the sentinel lymph node biopsy; 10. Extensive in situ carcinoma (EIC) 11. Multicentric or multifocal disease 12. Paget's disease of the nipple 13. Distant metastases 14. Lumpectomy cavity not well visualized on AccuBoost imaging 15. Lumpectomy cavity with 1cm margin (PTV) not adequately encompassed by any applicator (PTV > 6cm) 16. Breast separation with compression > 7cm. 17. Overlap of skin between orthogonal treatment axes
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically or cytologically confirmed breast cancer No previous interventional therapy for breast cancer Ability to provide written informed consent as per GCP and local regulations  Participation in other clinical study where the diagnosis and treatment protocol is stated prior to enrolment Inability to assess and follow up patient outcomes, for example quality of life due to psychiatric illness or WHO/ECOG performance status IV or worse
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 30.0-80.0,  Diabetes Patients followed in the diabetes units of the project area and doing regular consultations Patients with type 2 diabetes or treated or not with insulin Poorly controlled diabetes with HbA1c ≥ 8% Patients who accepted to undergo the whole process of peer education Patients who agreed to perform all biological measures included in the protocol Patients aged from 30 to 80 years old  Diabetic patients not carrying out their monitoring in diabetes units of the intervention area Patients followed in the diabetes units of the intervention area but not realizing their consultations regularly Patients with type 1 diabetes Severe complications within the preceding 3 months: infection, coronary complications, severe renal failure Concomitant illnesses threatening the functional or vital prognosis
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Be a female diagnosed by x-ray mammography (performed within 90 days prior to the study procedure) as having a solid breast mass or abnormal area without a mass Be scheduled for a biopsy (core / excisional / lumpectomy) of the mass or region of abnormality or for mastectomy within 30 days after this study procedure Be at least 18 years of age Be medically stable If a female of child-bearing potential, must have a negative pregnancy test Have signed Informed Consent to participate in the study  Males Females who are pregnant or nursing Patients whose breast lesion is unequivocally a cyst by unenhanced US Patients currently on chemotherapy or with other primary cancers requiring systemic treatment Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example Patients on life support or in a critical care unit Patients with unstable occlusive disease (eg, crescendo angina) Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia Patients with uncontrolled congestive heart failure (NYHA Class IV) Patients with recent cerebral hemorrhage
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infiltrating Bladder Urothelial Carcinoma Muscle invasive urothelial cancer (front line or following the progression of a superficial tumor), pT2-pT3 stage without lymphatic impairment (N0) and without detectable metastases (M0). An optimal macroscopic resection (TURB) have to be performed The proof of invasive tumor to the muscle should be brought by a transurethral resection under anaesthesia less than 8 weeks before or, in the absence, by superficial biopsies and formal imaging. Multiples biopsies in the bladder must also be performed Age ≥ 18 years Life expectancy ≥ 6 months Kanorfsky index ≥ 70 % (WHO 0, 1, 2) Biological neutrophils ≥ 1500/mm3, Platelets ≥ 100 000/mm3, haemoglobin ≥ 10 g/dl, creatinine clearance > 60 ml/mn No distant metastases (Thorax, abdomen, and pelvic CT-scan, bone scan) Efficient contraception for premenopausal women, maintained during the whole treatment and up to two months after the completion of radiotherapy No radiotherapy or chemotherapy history except for in situ bladder lesions No carcinological history except for non melanoma skin tumours, in situ uterine cervix cancer  Bladder tumors without any muscle infiltration Epidermoid carcinoma or adenocarcinoma Distance metastases or extrapelvic node positivity Severe digestive history (ulcerative colitis, complicated diverticulitis) Pregnancy and breast feeding
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Women with histologically proven invasive breast cancer and no distant metastases and Lymphnode negative and a clinical tumor classification of T2 (≥3.5cm)-T4 or with 1-3 positive lymph nodes and a clinical tumor classification of T2-T4 DCIS or LCIS are allowed in addition to invasive cancer at T2 or T3 level Age ≥ 18 years At least one lesion that can be accurately measured in two dimensions utilizing mammogram, ultrasound, or MRI images to define specific size and validate complete pathologic response Adequate bone marrow reserves (neutrophil count >1.5 x109 /l and platelet count >100 x109/l), adequate renal function (serum creatinine ≤ 1.5 x upper limit of normal) and hepatic function (ALAT, ASAT ≤ 2.5 x upper limit of normal, alkaline phosphatase ≤ 2.5 x upper limit of normal and total bilirubin ≤ 2.0 x upper limit of normal) Signed informed consent of the patient  Any patient with confirmed metastatic disease. Patients with inflammatory breast cancer Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails Quality Assurance or Quality Control criteria Patients who have had any prior chemotherapy, radiotherapy, or endocrine therapy for the treatment of breast cancer Any serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Vitamin D Deficiency Healthy women without major medical problem delivered at term and planning breastfeeding for next six months delivering term, single, infants with birth weight appropriate for gestational age without major health problem  Maternal endocrine disorders, disturbed calcium phosphorus homeostasis, anticonvulsant treatment Infants renal, hepatic insufficiency, endocrine disorders, congenital malformations, anticonvulsant treatment
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Women 18 years of age or older 2. Signed ICF 3. Women who have been histologically diagnosed with invasive ductal carcinoma or invasive lobular carcinoma of the breast prior to surgery 4. Planning breast preservation 5. Patients undergoing lumpectomy (partial mastectomy) procedure  Multicentric disease (histologically diagnosed cancer in two different quadrants of the breast) 2. Neoadjuvant systemic therapy 3. All T4 tumors 4. Previous radiation in the operated breast 5. Prior surgical procedure in the same quadrant 6. Implants in the operated breast 7. Pregnancy 8. Lactation 9. Participating in any other investigational study for either drug or device which can influence collection of valid data under this study
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatocellular Carcinoma Patients with histologically/cytologically confirmed HCC or radiographically diagnosed as per AASLD who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made Patients must have signed the informed consent form Patients must have a life expectancy of at least 8 weeks must follow the approved local product information  Prior treatment with sorafenib Concomitant participation in other clinical studies must follow the approved local product information
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Conditions or Focus of Study: *FDAAA (Enter 1 to 5 Items) Male or Female > 18 years, 2. Newly diagnosed stage I-IV breast cancer which is defined to meets any one of the following clinical or pathological staging (version 6.0 AJCC classification17) in Appendix B. 3. No prior therapy (other than surgery) for current disease, 4. Written informed consent (if required by local regulations)  Unable to receive definitive treatment 2. Unable to attend regular follow-up visit
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Breast Cancer Breast Cancer Stage II-III Informed consent form signed by the patient to accept study enrollment Female with pathologically confirmed diagnosis of primary invasive operable breast cancer, stage IIa-IIIc (6th edition of the AJCC Cancer Staging Manual), with tumors ≥ 2cm. Triple negative phenotype patients (RE and PR of less than 1% of stained cells by IHQ, IHC for HER2 of 0-1+ or ISH negative if 2/3+), according to local laboratory Age 18-75 years Adequate performance status (ECOG <2) Adequate renal and liver function and bone marrow reserve  Clinical or radiologic evidence of Metastatic disease Prior or concurrent anti-cancer therapy for current disease (hormone therapy, chemotherapy, radiotherapy, immunotherapy) Prior therapy with taxanes, anthracyclines or carboplatin for any malignancy Contraindication for study drugs (docetaxel or carboplatin) Serious concomitant systemic disorder that in the opinion of the investigator would compromise the patient's ability to complete the study, or have any other disease that could be worsened by chemotherapy or other potential support therapies
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Rhinitis Sinusitis Nasal Polyps above age 18 under age 80 patients with chronic rhinitis, sinusitis and nasal polyps patients candidates for surgery or medical therapy  Patients that had nasal surgery before smokers Diabetes, chemotherapy or radiation therapy Allergy to yeasts or pomegranate
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Locally Advanced Malignant Neoplasm Women older than 18 years old and younger than 70 years old Invasive breast cancer confirmed by core biopsy, any histology Tumor ≥2 cm and/or lymph node positive (proven by FNA)(T2-4b, N0-3, M0) Must have ER/PR positive and HER2 negative Must have full staging and extent disease and clinically and radiographically tumor measure Without previous treatment for breast cancer (including surgery, hormonotherapy or chemotherapy) Normal liver, kidney and blood tests Performance Status ECOG 0-2 o Karnofsky ≥70% Fasten glucose levels <125 mg/dl Signed consent  Previous use of metformin for any indication Presence of Diabetes Mellitus